Milestone Breakthrough in Precision Treatment for NF2-Related Schwannomatosis: Santo Therapeutics' ST002 Receives Dual FDA Designations

For patients with NF2-related schwannomatosis, life often begins its cruel descent in their twenties. Progressive hearing loss. Balance failures. Cranial nerve paralysis. By mid-adulthood, many face bilateral vestibular schwannomas—tumors wrapping around the nerves that control hearing and balance—alongside multiple meningiomas and spinal tumors. Surgery and radiation offer only temporary relief. Until now, no drug has ever received regulatory approval to slow the disease.

But a small Chinese biotech company founded just three years ago is challenging that therapeutic void. Santo Therapeutics, based in Hangzhou, has secured dual designations from the U.S. Food and Drug Administration for its gene therapy candidate ST002, marking what experts call a pivotal moment for a field long starved of breakthroughs.

On March 10, 2026, the FDA granted ST002 both Orphan Drug Designation and Rare Pediatric Disease Designation for the treatment of NF2-SWN. The twin recognitions, issued in rapid succession, underscore the severity of the unmet need and the therapeutic promise of Santo's approach.

NF2-SWN stems from loss-of-function mutations in the NF2 tumor suppressor gene, which encodes Merlin, a protein that links cell membranes to the cytoskeleton and keeps proliferation pathways like Hippo and PI3K-AKT in check. When Merlin fails, Schwann cells escape contact inhibition and multiply unchecked, forming tumors along critical nerves.

ST002 takes a direct aim at the genetic root. Built on Santo's proprietary 5G-LVV lentiviral vector platform, the therapy delivers a functional copy of the NF2 gene directly into tumor cells via intratumoral injection. The goal: restore Merlin expression, halt tumor growth, and trigger cancer cell apoptosis at the source. Preclinical studies in animal models showed significant tumor shrinkage without severe vector-related toxicity.

The world's first clinical trial for an NF2-SWN drug launched in February 2025 at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing, with Professor Li Ning serving as principal investigator. The trial, registered as NCT06834438, has already completed dosing in its dose-escalation phase. Early results are encouraging: no dose-limiting toxicities have emerged, and investigators have observed positive trends in tumor growth inhibition or shrinkage. Full data readout is pending.

"These FDA designations are an important validation of ST002 and its potential to address the high unmet need in NF2," said Dr. Zhou Lu, Santo's founder. "We will continue to focus on advancing ST002, always with safety, efficacy, and long-term clinical value at the core."

Nick Rodgers, Santo's honorary chairman, framed the stakes even more starkly: "NF2 is an extremely challenging area with almost no effective treatment options. Advancing gene therapy in this space has profound scientific and clinical significance."

Santo, founded in 2023, positions itself at the intersection of artificial intelligence and advanced therapy development. The company integrates virtual cell modeling, viral vector engineering, and immune cell reprogramming to build what it calls a next-generation intelligent lentiviral platform. While its primary focus is solid tumors, the technology extends to genetic diseases like NF2-SWN—precisely the kind of rare, severe condition where conventional drug development has historically failed to deliver.

The FDA's orphan drug designation grants Santo incentives including tax credits for clinical testing, exemption from prescription drug user fees, and, upon approval, seven years of market exclusivity in the United States. The rare pediatric disease designation adds further benefits, including priority review vouchers.

For a patient population that has waited decades for meaningful therapeutic options, the question is no longer whether help is coming—but how soon it will arrive.